title: Inhaled human insulin: an inspiration for patients with diabetes mellitus?
abstract: Inhaled insulin offers a novel option for controlling blood glucose levels in type 1 and type 2 diabetes, obviating the need for multiple daily injections. The first of several delivery systems, insulin Exubera, was recently approved by the US Food and Drug Administration (FDA). However, questions remain regarding its efficacy, cost-effectiveness, and possible deleterious effects on pulmonary function. This review will discuss the pharmacology, efficacy, important clinical trials, and practical aspects of inhaled insulin, and potential concerns associated with its use.
authors.affiliation: Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic Foundation, OH 44195, USA.
authors.forename: Michael B
authors.initials: MB
authors.lastname: Davidson
authors.forename: Adi E
authors.initials: AE
authors.lastname: Mehta
authors.forename: Elias S
authors.initials: ES
authors.lastname: Siraj
mesh_terms: D000280:Administration, Inhalation; D001786:Blood Glucose / Q000378:metabolism; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin